MaxLCBI4mm decreased during the administration of PCSK9i, and was maintained after cessation of PCSK9i. Plaque burden decreased in each observation.
By Coronary Lipid Plaques After Cessation of PCSK9i @gUPHI5nmNdxR41n
https://t.co/vYnTb35U8q
#circ_j https://t.co/ZzczrpjFw0
J-STAGE Articles - Clinical and Biomarker Profiles and Prognosis of Elderly Patients With Coronavirus Disease 2019 (COVID-19) With Cardiovascular Diseases and/or Risk Factors https://t.co/BdEH6UxUcJ